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Hemophilia A (HA) is a common X-linked recessive bleeding disease 
caused by mutations of FVIII gene. Inversion of intron 1 (inv1) and intron 22 
(inv22) are recurrent mutations in severe HA,  causing 50%  of cases. Inv1 has 
been reported to occur in 2–5% and inv 22 in 45% of  severe HA patients. Our 
objective was to determine, for the first time in Serbia, the frequency of inv1 and 
inv22  in a group of severe HA patients and to compare these data with those 
from other countries.  
Study subjects were 50 HA patients,  diagnosed and treated  from April 
2009 to June 2012  at Mother and Child Health Care Institute of Serbia “Dr 
Vukan  Cupic”  (IHS)  and    Institute  for  Child  and  Youth  Health  Care  of 
Vojvodina (IHV).The  presence of  inv1 and inv22  was analyzed using Inverse 
shifting PCR (IS-PCR). Our results revealed  that the frequencies of inv1 and 
inv22  in the cohort of Serbian patients were 6 % and  42% (34% of inv22 type I 
and 8% of  inv22 type II) respectively . These frequencies were in line with those 
found  in  other  populations.  Carrier  status  analyses  of    65  family  members 
(mothers and sisters) showed  the de novo inversion of intron 22 in one patient.  
Genetic Counseling Units of IHS and IHV provide the adequate genetic 
advice to all HA affected patients and their family members.  208                                                                                                            GENETIKA, Vol. 45, No.1,207-216, 2013 
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INTRODUCTION 
Hemophilia  A  (HA)  is  a  common  X-linked  recessive  bleeding  disease  affecting 
approximately 1 in 5000 men (KLINGE et al., 2002). It is caused by mutations in the FVIII gene ( 
F8 ) (MIM#306700), that has 26 exons spanning 186-kb genomic DNA and mapped to the distal 
end of the long arm of X-chromosome (Xq28) (GITSCHIER et al., 1984). These mutations can lead 
to FVIII protein deficiency or dysfunction. According to the residual plasma FVIII coagulant 
activity (FVIII: C), the disease can be divided into severe (<1%), moderate (1–5%) or mild (>5–
40%) HA (WHITE et al., 2001). The recurrent mutations in severe HA are the intron 1 and intron 
22 inversions, which occur in 2–5% and 45% of this patients, respectively (BAGNALL et al., 
2002); (LAKICH et al., 1993).  
According  to  latest  knowledge,  intron  22  includes  the  presence  of  a  bidirectional 
promoter that initiates transcription of two expressed genes (F8A and F8B). It is part of a GCrich 
sequence  of  9.5  kb  (int22h-1)  that  is  duplicated  at  two  positions  towards  the  Xq-telomere 
(int22h-2 and int22h-3). Sequencing of the human X chromosome has showed that int22h-2 and 
int22h-1 had the same orientation while int22h-3 is in inverse orientation to them; int22h-2 and 
int22h-3  are a part of an imperfect palindrome with a central unique loop of 67,3 kb and arms of 
50,5 kb (DE BRASI et al., 2008) (Fig. 1.A.).  
Intron  22  inversions  (inv22)  is  a  result  of  non-allelic  meiotic  homologous 
recombination between the int22h-1 region within the F8 locus and either int22h-2  or int22h-3, 
in male germ cells (ROSSITER et al., 1994). Int22h-1 recombines with the most telomeric copy of 
int22h which is always inversely oriented to int22h-1 and  in most of the cases it is int22h-3. 
This int22h-1/int22h-3 recombination lids to inv22 type I (Fig. 1A). In minor number of cases it 
was  shown  that  inversion  was  a  result  of  two  recombination  events.  First  one  was  a 
recombination  between  the  arms  of  the  palindrome  inv22h-2/  inv22h-3,  which  has  been 
established  as  a  common  non-deleterious  inversion  polymorphism.  That  event  swaps  the 
positions and orientations of int22h-2 and put it at the most telomeric and inverse position to 
inv22h-1.  The  second  recombination  between  inv22h-1  and  inv22h-2  result  in inv22  type  II 
(BAGNALL et al., 2005) (Fig. 1.B.). 
 Furthermore,  it  has  been  predicted  that  recombination  between  int22h-1  with  a 
similarly oriented copy of either int22h, int22h-2 or int22h-3 might be responsible for large 
deleterious  deletions  (Del22),  and  also  presumably  non-deleterious  duplications  (Dup22),  as 
opposed to the classical inversions (BAGNALL et al., 2006).  
Inversion of intron 1 (inv1) of F8 gene is another large molecular defect resulting in 
severe  HA.  The  pathogenic  mechanism  associated  with  this  inversion  involves  homologous 
recombination between a 1041 bp region of intron 1 (int1h-1) of the F8 gene and inversely 
orientated  an extragenic copy (int1h-2) of region  approximately 140 kb telomeric to the F8 
gene (BAGNALL et al.,  2002;  LAKICH et al., 1993)  (Fig1.C.). 
The  recombination  between  int1h-1  and  int1h-2  repeats  from  sister  chromatids  or 
homologous chromatids and chromosomes, would result in dicentric chromosomes and acentric 
fragments and hence should not lead to viable embryos. 
Both, the inv1 and inv22 prevent the formation of full-length F8 messenger RNA (mRNA) and 
result in the absence of F8 proteins leading to severe HA. N. ILIC et al: INVERSION OF INT1 AND 22OF F8  GENE IN SERBIAN POPUALTION                                       209 
Other HA-causative  mutations include a spectrum of nonsense, missense, splice-site 
mutations and small or large deletions ⁄ insertions that have been identified throughout the gene 
and compiled in international databases (HAMSTeRS, http://europium.csc.mrc.ac.uk). Due to its 
size and complexity, F8 still challenges mutation characterization worldwide. 
The goals of the present study were to assess the presence of inv22 and inv1 in the F8 
gene in Serbian severe HA patients and to compare these frequencies with published data from 
other populations. This study describes the first HA mutation series from Serbia. 
 
 
 
Fig. 1.  Mechanism of non-allelic homologous recombination causing inv22 and inv1 
A. Recombination between int22h-1 and int22h-3 in common palindrome int22h-2/ int22h-3 configuration, which cause 
inv22-type I. 
B. Intra-chromosomal/chromatid homologous recombination which yield an inverted palindrome configuration int22h-3/ 
int22h-2 and cause inv22-type II;  
C. Recombination between int1h-1 and inv1h-2 which cause inv1. 
 
 
MATERIALS AND METHODS 
Patients 
The study group includes 50 HA patients from 45 Serbian families who were diagnosed 
from April 2009 to June 2012   at Haemathooncology Departments of Mother and Child Health 
Care Institute of Serbia “Dr Vukan Cupic” (IHS) and Institute for Child and Youth Health Care 
of Vojvodina (IHV).  Blood samples from patients with clinical diagnosis of HA were analysed 210                                                                                                            GENETIKA, Vol. 45, No.1,207-216, 2013 
for the presence of inv 22 and inv1 of F8 gene. Also, the 65 of family members (26 mothers and 
39 sisters of patients) were under analyses for carrier status of mentioned inversions. 
Methods 
Clinical  diagnosis  of  HA  was  verified  by  APTT  (Activated  Partial  Thromboplastin 
Time) test  and quantification of FVIII:C. Peripheral blood samples (5-10ml) were collected in 
EDTA-Na2 tubes and DNA purification was carried out by the standard salting-out method. 
 
Inverse shifting-PCR (IS-PCR) 
IS-PCR for detection of inv22 and inv1 was performed according to L .C.ROSSETTI 
protocol (ROSSETTI  et  al., 2008).  Genomic  DNA  (2  µg)  was  digested  with  20 units  of  BclI 
according to  the  supplier’s  specifications  (Promega)  over 4  h  in  50 lL.  Digested DNA  was 
isolated using phenol–chloroform and ethanol precipitation. DNA fragments were circularized 
with 3 units of T4 DNA Ligase (Invitrogen) in 400 µlat 15 °C overnight. Ligated samples were 
then  treated  with  an  equal  volume  of  phenol:chloroform  mixture,  the  aqueous  phase  was 
removed, and the ethanol-precipitated DNA recovered in 50 µL of distilled water.  PCR was 
performed in reactions containing 3µl and 6 µl of circularized DNA for the analysis of Inv1 and 
Inv22, respectively, in the presence of 0.6 µM of each primer, 0.5 U of Taq DNA Polymerase 
(Promega) and additional standard PCR reagents in a total volume of 25 µL. Thermocycling 
involved 30 cycles of denaturation at 94 °C for 30 s, primer annealing at 56°Cfor 1 min and 
extension at 72 °Cfor1.5 min; cycling was preceded by 94°Cfor 2 min, and followed by 5 min at 
72 °C.  
IS-PCR  products  were  analyzed  on  ethidium  bromide  stained  1.5–2%  agarose  gel 
electrophoresis and photographed. 
 
Statistical analysis 
We performed the statistical analysis in order to compare the frequencies of inv22 and 
inv1 in FVIII gene in Serbian HA patients with similar published data  from other countries. 
Person χ
2  test and Fisher exact test (two- tailed) were used depending on the values of results 
(program Statistica 7). 
 
 
RESULTS 
In our cohort of 50 unrelated patients with severe HA, 24/50 (48%) were found to have 
the inversion.  The inv22 was detected in 21/50 (42%) of patients and in 3/50 (6%) the inv1 was 
revealed (Fig 2.). 
Four of 21 (4/21) patients with inv22 had inv22 type II (19%) and the rest of patients 
(17/21) was positive for inv22 type I (80,9%%) (Tab1.). In the present series of 50 patients, the 
frequency of inv22 type II was 8% (4/50) and 34% (17/50) for inv22 typeI. In 3/50 (6%) patients 
inv1 was found (Fig 2.). 
Carrier status analysis showed the presence of inversion in 25 mothers and 11 sisters of 
HA patients (Fig 2.). All analyzed mothers of hemophilic sons were carriers of the inversions, 
except in one case. According to these results in one HA patient inv22 type 1 occurred de novo. 
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Fig 2. The analysis of the IS-PCR products by standard agarose gel electrophoresis. 
 
A. Inv1 diagnostic test: (1) inv1 carrier; (2) inv1 hemophiliac; (3) non-inv1 individual and M indicates a marker of 100 
bp ladder. 
B. Inv22  diagnostic test: (1) inv22 type 1 hemophiliac; (2) inv22 type 1 carrier; (3)non-inv22 individual  and M indicates 
a marker of 100 bp ladder. 
C.  Inv22  complementary  test  for  full  characterization  of  all  possible  int22h-related  rearrangements  (i.e.  inversions, 
deletions and duplications depicted in inv22 diagnostic test): (1) inv22 type 1 hemophiliac; (2) inv22 type 1 
carrier; (3)non-inv22 individual  and M indicates a marker of 100 bp ladder. 
 
Tab.1. Frequency of inv22 and inv1 in Serbian patients with sever HA  
 
 
N° of  analyzed patients 
 
Positive for inversion 
 
Negative for inversion 
 
 
 
 
50(100%) 
Inv 22  Inv1   
 
 
 
 
 
 
26(52%) 
 
Type I  Type II   
 
 
 
3(6%) 
 
17(34%) 
 
4(8%) 
 
21(42%) 
 
24(48%) 
M     1      2      3  M       1       2       3  M      1        2        3 
224 
304 
bp  bp  bp 
487 
333  405 
457 
559 
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DISCUSSION 
The frequency of the recurrent inv 22 and inv1 in severe hemophilia A patients is about 
50% ( for inv22 40-50%, for inv1 2-5%), according to literature, without significant differences 
between  populations. (BAGNALL et al., 2002; LAKICH et al., 1993). In our study, for the first time 
performed in Serbian population, the frequency of inversions was in the same range ( 48%).    
The detected frequency of inv22 (42%), type I (34%) and type II (8%) in severe HA 
Serbian patients is similar to those observed in other populations. Comparison with the related  
studies  made  at  Germany  (OLDENBURG  et  al.,  2006),  Italy  (ACQUILA  et  al.,  2003),  Spain  ( 
CASAÑA et al., 2008), UK (BAGNALL et al., 2002), Mexico (MANTILLA-CAPACHO et al., 2007), 
Argentina (ROSSETTI  et al., 2004), Brazil (LEIRIA et al., 2009), India (FARIDI et al., 2012) and 
China (XUE et al., 2010) did not show statistically significant differences (Tab. 2.).Our results are 
also consistent with an international consortium study where 43% of 2093 unrelated severe HA 
patients were positive for inv22 (35% type  I and 7% type II) (ANTONARAKIS et al.,1995). 
The  suggested  prevalence  of  inv1  in  literature  is  2-5%  in  general  population  of 
hemophilia A patients, what correspond with our results of 6%. When we compared our data 
with those from 9 other countries we did not observe the significant difference, except for the 
samples from Mexico (Tab.2.). The incidence of inv1 in this country was 0%. The larger studies 
from these countries are required before the validation of any ethnic differences. 
All published studies, so far, including ours, verified that the inv1 occurred at about one 
tenth the frequency of the inv22. This may largely be due to the size of the int1h repeats that are 
9-fold smaller than int22h (1041 versus 9503bp). Additional reason could be the presence of 
only one exstrogenic copy of int1h, whereas two int22h copies.  The similarity between copies of 
int1h is very high (99.9%), as it is between repeats of int22h, so the degree of similarity should 
not be responsible for the difference in frequency of above mentioned inversions (BAGNALL et 
al., 2002).  
According  to    carrier  status  investigation,  mother  of  hemophilic  son  has  an 
approximately 80% chance of being a carrier when her son is the first affected individual in the 
family, and this chance is even higher (98%) if  only inv22 is considered (LEUER et al., 2001). 
These  results  may  be  due  to  somatic  mosaicism  which  predominantly  occurs  in  a  female 
members of family. Germline mosaicism is rare. Intrachromosomal recombination among the 
homologous regions of intron 22 is thought to be almost exclusively of meiotic origin, arising 
predominantly in male germ cells, so this pathogenic mechanism would argue against a somatic 
origin of an intron 22 inversion during early embryogenesis. However, one instance of somatic  
mosaicism  with  this  mutation  type  has  been  observed  (OLDENBURG  et  al.,  2000).  Somatic 
mosaicism of the intron 22 inversion caused by a post-zygotic de novo mutation would imply 
that this mutation is not, as suggested before, exclusively restricted to meiotic cell divisions, but 
it may also occur during mitotic cell divisions either in germ cells or in somatic cells. 
In our study, were 25 mothers had been analyzed for carrier status of inv22 and inv1, 
we found only one case with non carrier mother. So, the inv22 in one HA  patient we considered 
as de novo mutation.  The IS –PCR method which we used for inv22 detection was able to reveal 
minimal mosaic composition of 5% (ROSSETTI et al., 2008). According to that, inv22 in our 
patient may be due to the presence of low percent of mosaicism in mother’s somatic cells or to 
some post-zigotic event in patient’s somatic cells.  
In 45 families with HA we also detected 11 sisters who were carriers of recurrent inversions.  N. ILIC et al: INVERSION OF INT1 AND 22OF F8  GENE IN SERBIAN POPUALTION                                       213 
Genetic counseling units of HIS and IHV  provide the adequate genetic advice to all HA 
affected patients and their family members. 
 
Tabela 2. Prevalence of inv22 and inv1in different ethnic populations 
Ethnic population 
(Reference) 
Frequency 
of inv22 
%  Significance  Frequency of inv1  %  Significance 
          Europe 
Serbia  
(this article) 
21/50  42  /  3/50  6  / 
Germany  
(OLDENBURG et al.,2006) 
 
339/753  45  0,68  19/753  2,5  0,15 
Italy  
(ACQUILA et al., 2003) 
39/93  42  1  3/54  5  0,66 
Spain 
 (P CASAÑA et al., 2008) 
42/102  41  0,92  4/134  3  0,66 
UK 
(BAGNALL et al., 2002) 
94/209  45  0,71  10/209  5  0,99 
         America 
Mexico 
(MANTILLA-CAPACHO et al., 
2007) 
14/31  45  0,77  0/65  0  0,08 
Argentina (ROSSETTI et al., 
2004) 
25/64  39  0,75  1/64  1,5  0,31 
Brazil  
(LEIRIA et al., 2009) 
46/107  43  0,92  3/107  2,8  0,40 
         Asia 
India 
(FARIDI et al., 2012) 
35/80  44  0,84  3/80  3,8  0,68 
China  
(XUE et al., 2010) 
57/148  39  0,66  3/148  2  0,34 
 
CONCLUSION 
The first study performed on Serbian hemophilia A patients showed that the frequency 
of inv22 (42%) and inv1 (6%) was in line with similar published data from other countries. The 
further molecular analyses should be performed on HA patients lacking inv22 and inv1, in order 
to detect the other underlying mutations, which cause this disease. 
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Izvod 
Hemofilija    A  (HA)  je  X-vezano  recesivno  oboljenje  koje  nastaje  kao  posledica 
mutacija u genu za faktor koagulacije VIII (F8).  Do sada je identifikovan veliki broj različitih 
tipova mutacija u F8 genu, od kojih su najučestalije inverzija introna  1 (inv1) i inverzija introna 
22 (inv22). Ove mutacije  su prisutne kod 50% obolelih od teškog oblika HA;  inv1 je otkrivena  
kod 2–5%, a inv22 (inv22) kod 45% pacijenata. Cilj ove studije je bio da se odredi  učestalost 
pomenutih inverzija u grupi  HA pacijenata iz Srbije, jer do sada ovakvi podaci nisu publikovani. 
Analiza je urađena na uzorku od 50 obolelih kojima je u period od aprila 2009. do juna 
2012. HA dijagnostikovana  na  Institutu za zdravstvenu zastitu majke i deteta Srbije, ,,Dr Vukan 
Čupić"  (IMD)  i  Institutu  za  zdravstvenu  zaštitu  dece  i  omladine  Vojvodine  (IZZZDIO).  Za 
detekciju inv1 i inv22 korišćena je metoda inverznog PCRa (IS-PCR). Rezultati su pokazli da u 
analiziranom uzorku HA pacijenata iz Srbije učestalost inv1 iznosi 6%, a inv22 42% (34% inv22 
tip I, 8% inv22 tip II). Ovi rezultati  se slažu sa objavljenim rezultatima sličnih studija iz drugih 
zemalja. Analiza za određivanje statusa nosioca inverzija urađena je kod 65 članova porodica  
obolelih (majke i sestre) i ona je pokazala prisustvo de novo inv22 kod jednog pacijenta.  
Svi oboleli od HA, kao i članovi njihovih porodica, dobili su odgovarajući genetički 
savet u okviru Genetičkog savetovališta IMDa i IZZZDIOa. 
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